source
- Lilly signs $5.9B deal with Stipple to unlock oncology targetsEli Lilly has struck a $5.9 billion deal to partner with Stipple Bio on oncology drug candidates that more precisely target tumor cells.Fierce Biotech · 8h ago↗ source
- J&J to acquire Ollin Biosciences for $2.2 billion to advance bispecific eye drug OLN324 against Roche’s VabysmoJohnson & Johnson announced it will buy Ollin Biosciences for an upfront $2.2 billion, with additional regulatory and commercial milestones that could bring total payments to about $3.3 billion. O…